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Abstract
A genome-wide association study was performed to identify genetic factors involved in susceptibility to psoriasis (PS) and
psoriatic arthritis (PSA), inflammatory diseases of the skin and joints in humans. 223 PS cases (including 91 with PSA) were
genotyped with 311,398 single nucleotide polymorphisms (SNPs), and results were compared with those from 519 Northern
European controls. Replications were performed with an independent cohort of 577 PS cases and 737 controls from the U.S.,
and 576 PSA patients and 480 controls from the U.K.. Strongest associations were with the class I region of the major
histocompatibility complex (MHC). The most highly associated SNP was rs10484554, which lies 34.7 kb upstream from HLA-
C (P = 7.8610211, GWA scan; P = 1.8610230, replication; P = 1.8610239, combined; U.K. PSA: P = 6.9610211). However,
rs2395029 encoding the G2V polymorphism within the class I gene HCP5 (combined P = 2.13610226 in U.S. cases) yielded
the highest ORs with both PS and PSA (4.1 and 3.2 respectively). This variant is associated with low viral set point following
HIV infection and its effect is independent of rs10484554. We replicated the previously reported association with interleukin
23 receptor and interleukin 12B (IL12B) polymorphisms in PS and PSA cohorts (IL23R: rs11209026, U.S. PS, P = 1.461024; U.K.
PSA: P = 8.061024; IL12B:rs6887695, U.S. PS, P = 561025 and U.K. PSA, P = 1.361023) and detected an independent
association in the IL23R region with a SNP 4 kb upstream from IL12RB2 (P = 0.001). Novel associations replicated in the U.S.
PS cohort included the region harboring lipoma HMGIC fusion partner (LHFP) and conserved oligomeric golgi complex
component 6 (COG6) genes on chromosome 13q13 (combined P = 261026 for rs7993214; OR= 0.71), the late cornified
envelope gene cluster (LCE) from the Epidermal Differentiation Complex (PSORS4) (combined P = 6.261025 for rs6701216;
OR 1.45) and a region of LD at 15q21 (combined P= 2.961025 for rs3803369; OR = 1.43). This region is of interest because it
harbors ubiquitin-specific protease-8 whose processed pseudogene lies upstream from HLA-C. This region of 15q21 also
harbors the gene for SPPL2A (signal peptide peptidase like 2a) which activates tumor necrosis factor alpha by cleavage,
triggering the expression of IL12 in human dendritic cells. We also identified a novel PSA (and potentially PS) locus on
chromosome 4q27. This region harbors the interleukin 2 (IL2) and interleukin 21 (IL21) genes and was recently shown to be
associated with four autoimmune diseases (Celiac disease, Type 1 diabetes, Grave’s disease and Rheumatoid Arthritis).
Citation: Liu Y, Helms C, Liao W, Zaba LC, Duan S, et al. (2008) A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease
Loci. PLoS Genet 4(3): e1000041. doi:10.1371/journal.pgen.1000041
Editor: Suzanne M. Leal, Baylor College of Medicine, United States of America
Received September 27, 2007; Accepted February 28, 2008; Published April 4, 2008
Copyright:  2008 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by NIH grant R01 AR050266 (AMB), K01DA015129 (NLS) and TSRHC grant 0305756 (CAW).
Competing Interests: Patent application on findings in process.
* E-mail: bowcock@genetics.wustl.edu
Introduction
Psoriasis (PS) is a chronic inflammatory disease of the skin
affecting 2–3% of the population [1]. Approximately 25% of
patients also develop psoriatic arthritis (PSA), a common,
debilitating auto-immune disease belonging to the family of
spondyloarthritides [2,3]. The recurrence risk (lS) of PSA is high,
and estimates of 27–47 have been proposed [4,5]. This is much
higher than the estimated lS of PS which is estimated to be
between 4 and 11[6].
PS and PSA are interrelated disorders, and the prevalence of PS
is 19 times higher among first degree relatives of probands with
PSA compared with the general population [7]. The pathogenesis
of PS and PSA is complex, involving both genetic and
environmental risk factors. Strong association of PS with the
MHC class I region (PSORS1 or psoriasis susceptibility locus 1)
was demonstrated in the 1970s [8] and has been confirmed in
numerous subsequent studies [9–11]. However, the genetics of
PSA is not as clear-cut and association with alleles of the HLA
class I region is not reported to be as strong with PSA as with PS
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[7]. Hence, it has not been clear if PSA is a clinical phenotype that
is distinct from PS without psoriatic arthritis and if is due to
different predisposing genetic factors.
A number of regions in the genome have been reported to be
associated with PS [1,12–14], and some have been convincingly
replicated. This includes the 3’UTR of interleukin 12B (IL12B)
[15,16] and two non-synonymous SNPs of interleukin 23 receptor
(IL23R) [16]. One of these (R381Q) was also shown to be
associated with Crohn’s disease [17]. However, together with the
PSORS1 locus, the combined effect of these loci is unable to
account entirely for genetic susceptibility to PS.
In order to systematically search for other susceptibility loci, we
undertook a genome wide association (GWA) scan to identify
genetic factors predisposing to PS and PSA. Besides detecting
strong association with the HLA class I region in the combined
and PSA cohort, and replicating the recently reported associations
with IL23R and IL12B, we identified a number of novel
associations. These include a region on chromosome 13q13
harboring LHFP and COG6, a region on chromosome 15q21
harboring USP8-SPPL2A-TNFAIP8L3, association with the LCE
cluster of genes on chromosome 1q21 from the PSORS4 locus,
and a region of chromosome 4q27 recently reported to be
associated with several other autoimmune diseases and associated
with PSA and potentially PS.
Results/Discussion
For our ‘‘discovery’’ phase, 223 PS cases (132 cases with PS
without arthritis and 91 PS cases with arthritis (PSA) were typed
on the Illumina HumanHap300 arrays. We compared case data to
publicly available genotype data of 519 European controls from
the New York Cancer Project[18] collected with the same
platform. The number of cases used for this scan is smaller than
that used in many recently described genome wide association
scans. However, the 91 cases of PSA had at least one first degree
relative with PS and were expected to be enriched for genetic
factors. Power calculations based on 223 controls and 519 controls
indicated that using a threshold of P,561025, we had 70% power
of detecting a locus with a genotype relative risk (GRR) of 2.0, and
over 99% power to detect a locus with a GRR of 3.0 such as the
MHC (see below). However, many replicated associations have
small GRRs [19] and we had only 10% power of detecting a locus
with a GRR of 1.5.
Following the genotyping of samples, stringent quality control
measures were implemented. We required that all samples used for
the discovery phase passed a 93% genotyping call rate threshold,
and that all SNPs passed a 95% call rate threshold. Justification for
this threshold is based on the evaluation of empirical distributions
(Figures S1 and S2). With sample call rates #93%, there was an
elevation in observed sample heterozygosity, i.e. deviation from
Hardy-Weinberg equilibrium, suggesting possible genotyping
errors (e.g., sample contamination or allele drop-out). Likewise,
there was a significant discrepancy of missingness between case
and control groups when the SNP success rate was ,95%.
For the discovery phase, a total of 311,398 SNPs were pruned to
305,983 SNPs after filtering for low call rate, minor allele
frequency ,0.01 and deviation from Hardy-Weinberg equilibri-
um (P,0.001). Quality control also led to the removal of 29
samples, leaving 218 cases for further analysis (Table S1). The
average genotyping rate in the remaining individuals was 0.995.
To investigate other biases[20] that could be introduced with
shared controls, we assessed the median distribution of test
statistics using the genomic-control factor lGC[21]. With a set of
463 ancestry informative SNPs (AIMs), lGC= 1 indicating no
inflation). We also performed analysis on the same set of AIM
SNPs with STRUCTURE software[22]. Under the assumption of
two population clusters, there was no association between the most
likely inferred cluster and case/control status and the average
allele frequency difference between clusters was less than 2.5%.
These results showed that population substructure is unlikely to be
confounding our results. However, analysis of all markers used in
the discovery study yielded lGC= 1.101 before correction (Q-Q
plot shown in Figure S3). A similar value was obtained with
EIGENSTRAT [23] where l=1.107. Examining stratified subsets
of cases (PS without arthritis or PSA) with all markers also yielded
similar l values (PS without arthritis: lGC= 1.07; PSA:
lGC=1.05). Following adjustment of P values with the genomic
control method, l= 1˜ The discovery P values adjusted by the
genomic control method as implemented in PLINK[24] are
presented in the tables and figures.
To detect associations, we first performed a preliminary analysis
with a Cochran-Armitage trend test [25]. Figure 1 illustrates
negative logarithm of the P values obtained across the genome,
considering all cases and all controls (Figure 1A) and considering
only the 91 PSA cases and all controls (Figure 1B). Results were
then rank ordered on the basis of P values. 84 SNPs in 35 genomic
regions were associated with P,561025; a level that we would
informally expect to observe by chance roughly 15 times in this
scan given the number of tests performed if all SNPs were
independent. A subset of SNPs from 120 regions were investigated
further. Criteria for selection included the strength of the discovery
P value, particularly when several SNPs from a single region
showed evidence for association, a possible biological role of a
gene harboring a SNP with some evidence for association, or
localization of SNPs with moderate evidence for association to a
known psoriasis susceptibility locus (e.g. PSORS4). We also
included the previously reported associated SNPs in IL23R and
IL12B[16].
An independent cohort of 577 PS cases from the U.S. and 737
U.S. controls were used for the replication stage; 94 of these cases
had also been diagnosed with PSA. To examine the potential role
Author Summary
Psoriasis (PS) and psoriatic arthritis (PSA) are common
inflammatory diseases of humans affecting the skin and
joints. Approximately 2% of Europeans are affected with
PS, and ,10–30% of patients develop PSA. Genetic
variation in the MHC (multiple histocompatibility locus
antigen cluster) increases risk of developing PS. However,
only ,10% of individuals with this risk factor develop PS,
indicating that other genetic effects and environmental
triggers are important. Recent approaches using a case/
control approach and genome wide association studies
with DNA markers known as SNPs (single nucleotide
polymorphisms) have been fruitful in identifying genetic
factors for common diseases. This study describes the first
large scale genome wide scan for additional PS and PSA
susceptibility genes using 233 cases and 519 controls. It
revealed that the MHC is truly the most important risk
factor for PS and that it plays a very major role in PSA,
confirmed recently identified associations with interleukin
23 receptor and interleukin 12B in both PS and PSA, and
identified new associations. These include a region on
chromosome 4q27 that contains genes for interleukin 2
and interleukin 21 that has been recently implicated in
other autoimmune diseases, and seven additional regions
that include chromosome 13q13 and 15q21.
Genome-Wide Association Study of Psoriasis
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of variants upon PSA susceptibility specifically, 576 PSA cases
from the UK and 480 controls from the UK were also employed.
An alternative genotyping technology (iPlex; Sequenom) was used
for the replication phase. The platforms used for the discovery and
replication phases gave very similar results: Concordance rates on
the basis of 116 samples and 301 SNPs typed with both platforms
was 98.74%.
Our 100 top ranked SNPs with any cohort (PS, PS without
arthritis, or PSA) are listed in Table S2, to facilitate future attempts
to replicate our findings. A total of 289 SNPs, including SNPs from
the MHC, and two previously reported associated SNPs within
IL12B and IL23R[16] were genotyped in the replication analysis.
MHC
The MHC, and in particular, the HLA class I region, is the only
region that has been shown to be consistently associated with PS.
The first nine top-ranking SNPs were from the MHC and seven
were significant, even when adjusted with the Bonferroni
correction for multiple tests (Table S2). Overall, 32 SNPs from
the MHC had adjusted P values ,561025 (Figure 2, Table S2).
The most significant association was with rs10484554 (adjusted
P=7.8610211, GWA scan; P = 5.61610228, replication;
P = 9.772610238, combined) (Figure 2, Table 1). This SNP lies
34.7 kb upstream from the transcriptional start site of HLA-C.
Strongest association with this region is consistent with previous
results from our group and others [9–11]. The rs10484554*T
allele had frequencies of 0.325 in U.S. cases and 0.15 in U.S.
controls (OR: 2.8 (95% CI: 2.4–3.3). To determine the
relationship of this allele with the classical HLA-C allele strongly
associated with psoriasis (HLA-Cw*0602), we investigated the
transmission of this allele with classical HLA-C alleles in ,250
nuclear families with psoriasis that we have reported elsewhere
[26]. The rs10484554*T allele was detected on nearly all
haplotypes with HLA-Cw*0602 or HLA-Cw*1203 alleles (results
not shown), and was also strongly correlated with the previously
described highly associated PSORS1 SNP n9*G[26,27]
(rs10456057*G) allele. We have previously shown that SNPs
upstream from HLA-C are more strongly correlated with PS than
HLA-Cw*0602 is, and that these risk alleles are also correlated
with HLA-Cw*1203 [26]. Hence, rs10484554*T may be a good
proxy for the PSORS1 variant.
In the case of the U.K. PSA replication samples, rs10484554
was again highly significant (P = 6.86610211) (Table 2), although
the frequency of the rs10484554*T allele exhibited population
differences when frequencies in the U.K. and U.S. were
compared. In the U.K. the rs10484554*T allele was found at a
lower frequency in cases and controls (0.19 and 0.07 respectively;
OR: 2.4 (95% CI: 1.8–3.1)).
A second SNP from the HLA class I region lying between
MICA and MICB (rs2395029) was highly associated with PS and
PSA. This SNP results in the G2V polymorphism of the class I
gene HCP5 (HLA complex P5) which encodes an endogenous
retroviral element. For this SNP, PS was associated with a
combined P=2.13610226 in the U.S. cohort and 1.86610210 in
the U.K. PSA cohort (Table 1, Table 2). The OR of the
rs2395029*C allele with both PS and PSA was higher than with
any other SNP tested (4.1 and 3.2 with PS and PSA respectively).
This allele was found at a frequency of ,0.12 in cases and 0.04 in
controls and did not exhibit the population frequency differences
of rs10484554. The LD relationship between rs2395029 and
rs10484554 is not strong (r2 = 0.33 in European CEPH HapMap
samples and r2 = 0.23 in our U.S. case/control cohort). Condi-
tioning upon rs10484554, the P value for rs2395029 was still
significant (P = 7610210), hence effects from this SNP are likely to
be independent.
HCP5 is expressed primarily in cells of the immune system such
as spleen, blood and thymus (http://smd-www.stanford.edu/),
consistent with a potential role in autoimmunity. This allele was
Figure 1. Summary of genome-wide association scan results for all cases and the PSA subgroup. Negative LOG10 P values for the
Cochran-Armitage test of trend for genome-wide association across the genome and by chromosome are shown. Trend P values were adjusted with
the genomic control (GC) method. The spacing between SNPs on the plot is uniform and does not reflect actual physical distances. Adjacent
chromosomes are shown in red and then in blue. The horizontal dashed lines display a cutoff of P = 561025. A: Results obtained with all cases. B:
Results obtained with the subgroup of 91 psoriatic arthritis cases (PSA).
doi:10.1371/journal.pgen.1000041.g001
Genome-Wide Association Study of Psoriasis
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recently shown to explain 9.6% of the total variation in viral set
point following HIV-1 infection[28]. This is of interest, since
psoriasis can be triggered by infection with HIV and other viruses.
Hence, it is possible that HCP5-C carriers mount a strong immune
reaction to viral infection, but that in genetically susceptible
individuals, this reaction leads to excessive inflammation in skin
and joints. Overall, our observations indicate that MHC class I
region SNPs are more highly associated with both PS and PSA
than any other SNPs.
IL23R associations
A recent global association scan using a set of pooled PS samples
and controls against a set of 25,215 genecentric SNPs confirmed a
previously reported association with IL12B (rs3212227 in its 39
UTR) [15] and identified a second region of association 60 kb
upstream from its mRNA start site (rs6887695) [16]. An analysis of
additional genes encoding components of the IL12B pathway lead
to the identification of associations with Il23R (R381Q:
rs11209026 and L310P: rs7530511) [16]. These SNPs were
Figure 2. Association localization plots for the MHC following discovery and replication phases. Results for SNPs used in the discovery
phase (adjusted for GC) are presented as diamonds. Negative LOG P values are provided on the Y axis. The X axis corresponds to the locations of
SNPs. The P value for all samples (original GWA scan plus replication samples) are shown as circles. The P value obtained with the most highly
associated SNP (from the original GWA scan plus the replication samples) is shown as a red circle. The SNPs shown as orange diamonds are in r2.0.8
(European HapMap CEPH (CEU) samples) with the most significant SNP identified in our study. The recombination rate based on the CEU HapMap is
shown in light blue along the x axis (scale on the right). The LD relationship of Illumina discovery SNPs derived from CEU HapMap genotypes are
shown below the graph. The most highly associated SNPs are indicated with an asterisk. The green arrows indicate the locations of select genes.
doi:10.1371/journal.pgen.1000041.g002
Genome-Wide Association Study of Psoriasis
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proposed to mark a common psoriasis-associated haplotype.
Rs11209026 is also the SNP within IL23R reported to be
associated with Crohn’s disease[17].
In our discovery cohort, the most significant association in the
IL23R interval was obtained with a different SNP from that
described previously as being associated with PS (rs11209026).
This SNP, where P= 0.0039 in the discovery cohort (Table 1), has
not previously been reported to be associated with PS. The LD
relationship between rs12131065 and the previously associated
rs11209026 SNP is low (r2=0.031 in HapMap CEPH European
samples; 0.009 in cases; 0.026 in controls). Conditioning upon
rs11209026, the P value for rs11209026 was 0.013. Hence, effects
from this SNP may be independent of rs11209026 and its
association with PS should be investigated in other cohorts.
SNP rs12131065 lies downstream from IL23R (63 kb from
rs11209026) and 4.041 kb upstream from the gene for interleukin
12 receptor B2 (IL12RB2) (Figure 3). IL12RB2 is involved in IL12
dependent signaling, is upregulated by gamma interferon in Th1
cells and plays a role in Th1 differentiation[29]. Association with a
SNP closer to IL12RB2 than IL23R is of interest since animals
where IL12RB2 is inactivated develop autoimmune disease[30].
Association with the previously reported IL23R associated SNP
rs11209026 in the discovery cohort was not significant (adjusted
P= 0.081). Genotyping of rs11209026 and rs12131065 in the U.S.
replication cohort yielded combined P values of 1.461024 and
0.001 respectively (Table 1) consistent with replication of this locus
with respect to previous studies. In the case of these two SNPs, the
protective T and A alleles were found at frequencies of ,0.04 and
0.2 in cases versus ,0.07 and ,0.24 of controls respectively. In
the U.K. replication PSA cohort, association with rs11209026 was
consistent with replication (P= 8.361024), with the rs11209026*T
allele being found at frequencies of ,0.04 in cases and ,0.08 in
controls (Table 2).
IL12B Associations
Although the associated IL12B SNPs rs3212227 and rs6887695
were not interrogated by the Illumina screening panel of SNPs
used here, typing of these SNPs in our replication U.S. case/
control cohorts yielded P values of 0.021 and 561025 and
replicated previously reported associations (Table 1). In the U.K.
PSA cohort, association with rs6887695 was also consistent with
replication (P = 0.0013) (OR: 0.69; 95% CI: 0.56–0.85)) (Table 2).
Novel Psoriasis Loci
In the discovery cohort, there were four SNPs from 13q13
where P,561025 (adjusted P,261024). These were: rs1186468,
rs4514547, rs4569133 and rs7993214 (Table S2). These SNPs lie
within a region on chromosome13q13 that encodes the conserved
oligomeric golgi complex component 6 (COG6) gene and a lipoma
HMGIC fusion partner (LHFP)[31]. Three of the top associated
SNPs were tested in the U.S. replication cohort, and all showed
evidence of replication at P,0.05 (Table 3, Figure 4). Results were
most significant with rs7993214 (adjusted P =1024, GWA scan;
P= 0.0033, replication; P= 261026, combined). Rs3812888,
(adjusted P= 0.0017, GWA scan; P= 461024, replication;
P= 1025, combined) was the only SNP where replication results
would remain significant following the stringent Bonferroni
correction for multiple tests (P = 0.048). The OR of the
rs3812888*C allele was 1.38 (95% CI: 1.15–1.66). The
rs3812888*C allele was found at frequencies of 0.43 in cases and
0.35 in controls.
COG6 is a component of the conserved oligomeric golgi (COG)
complex and is involved in intracellular transport and glycoprotein
modification[32]. The glycosylation pathways in the golgi
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Figure 3. Association localization plots for the ILI23R region on chromosome 1. Symbols are the same as those used in Figure 2. SNPs
indicated with an asterisk are rs11465804, rs11209026 (R381Q) and rs12131065.
doi:10.1371/journal.pgen.1000041.g003
Table 2. Summary of association with previously reported PS susceptibility loci in U.K. PSA cohort (576 cases, 480 controls).
SNP Gene/Region Trend P value Minor allele Freq. UK PSA cases Freq. UK PSA controls OR UK PSA (95% C.I.)
rs10484554 MHC 6.86610211 T 0.19 0.07 2.4 (1.8, 3.1)
rs2395029 MHC 1.86610210 C 0.12 0.04 3.2 (2.2, 4.6)
rs11209026 IL23R 0.00083 T 0.043 0.079 0.52 (0.35, 0.77)
rs12131065 IL23R 0.31 A 0.21 0.23 0.89 (0.72, 1.11)
rs3212217 IL12B N.D. G N.D. N.D. N.D.
rs6887695 IL12B 0.0013 C 0.213 0.28 0.69 (0.56, 0.85)
UK PSA: U.K. Psoriasis cases with arthritis; OR: Odds Ratio; C.I.: confidence interval; N.D.: Not Done.
doi:10.1371/journal.pgen.1000041.t002
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apparatus must be intact for protein secretion to continue
unabated. In C. elegans, a COG complex is required to glycosylate
an ADAM protease (a disintegrin and metalloprotease)[33]. In
humans, variants within some ADAM genes lead to inflammatory
diseases. For example, ADAM33 is an asthma susceptibility gene
whose catalytic domain undergoes glycosylation[34]. Recent
genetic studies suggest that ADAM33 is a psoriasis susceptibility
gene as well [35]. Hence, COG6 could be involved in
glycosylation of ADAM33 or other ADAM proteases. Staining
of skin sections with a COG6 antibody revealed cytoplasmic
staining in the epidermis as well as strong T-cell staining (Figure 5).
There was variable expression of the protein in non-lesional skin
samples, but there was uniformly strong expression in all lesional
sections. Very little is known about LHFP. It is a subset of the
superfamily of tetraspan transmembrane protein encoding gene.
Expression analysis from SOURCE (http://smd-www.stanford.
edu/) indicates that highest levels are found in the ear and spinal
cord.
When the PSA discovery cohort (n = 91) was analyzed
separately, four SNPs from a region on chromosome 15q21
between ubiquitin specific protease 8 (USP8) and tumor necrosis
factor, alpha-induced protein 8-like 3 (TNFAIP8L3) were
associated with P,561025 (Table S2). In the case of the most
highly associated SNP (rs4775919), adjusted P=6.761026.
Following replication genotyping, this and rs3803369 were
associated with PS with P values consistent with replication (for
rs3803369, adjusted P= 2.561024, GWA scan; P = 0.013, repli-
cation; P= 2.961025 combined; Table S2, Table 3, Figure 6). The
rs3803369*A allele was found at a frequencies of,0.2 in cases and
0.15 in controls (OR 1.43, 95% CI: 1.21–1.69). Other genes in this
region include the transient receptor potential melastatin 7
(TRPM7)[36], signal peptide peptidase like 2a (SPPL2A)[37]
and AP4E1, a member of the heterotetrameric adaptor protein
(AP) complexes (Figure 6). TNFAIP8L3 is a novel protein. It
harbors a domain (DUF758) that is found in several proteins
induced by tumor necrosis factor alpha (TNFA), but its function is
unknown. However, the most plausible candidate is SPPL2A that
catalyzes the intramembrane cleavage of TNFA, triggering the
expression of IL12 by activated human dendritic cells[38].
Staining of skin sections with an SPPL2A antibody (Figure 5)
revealed profound staining of the epidermis, and staining of some
dermal cells in both lesional and non-lesional skin.
This region is also of interest however, because a processed
pseudogene for one of the genes in this region (USP8) is found
upstream from HLA-C[27]. As discussed earlier, this region is one
that is most likely to harbor the PSORS1 variant. To ensure that
our observations were not due to cross-hybridization of chromo-
some 15q21 SNPs with PSORS1 SNPs, we investigated alignment
of genes from this region of chromosome 15q21 with the
remainder of genome. We did not detect any significant identity
with any other region, including the MHC. This, and the fact that
chromosome 15 associated SNPs are in Hardy-Weinberg
equilibrium indicate that our results are unlikely to be artifactual
and due to amplification of PSORS1 sequences. The similarity
between the PSORS1 and 15q21 variants and their biological
consequences need to be investigated further since it may provide
important insights into the nature of the PSORS1 variant.
However, it is worth noting that our PSA cases which provided
strongest evidence for association with 15q21 all had at least one
first degree relative with PS, and association with this locus may be
harder to detect in ‘‘sporadic’’ cases.
We also observed association of PS with a region of the Epidermal
Differentiation Complex (EDC), which harbors a previously
established psoriasis locus (PSORS4)[39]. In this instance,
rs6701216 yielded a combined P=6.261025 (OR 1.45) (Table 3,
Figure S4). This SNP lies within the late cornified envelope 1C gene
(LCE1C)[40], and is one of a family of genes that are transcribed
very late in epidermal differentiation. Our localization of PSORS4 to
the LCE region is of interest, and its refinement will be described in
detail elsewhere (Robarge et al., in preparation).
There were two other regions selected for follow-up where P
values were ,0.05 in the PS replication cohort, and where
evidence for association increased in the combined cohort
(Table 3). One was an intergenic region located between
granulysin (GNLY) and atonal (ATOH) on chromosome 2p11.
The most highly associated SNP was rs2164807 (adjusted
P= 0.0015, GWA scan; P = 0.0039, replication; P= 1.661025
combined). For this SNP, the G allele was found at a frequency of
,0.47 in cases and ,0.39 in controls (OR: 1.35, 95% CI: 1.18–
1.54). GNLY (Protein NKG5, Lymphokine LAG-2) is of
considerable interest with respect to psoriasis. It is present in
cytotoxic granules of cytotoxic T lymphocytes and natural killer
cells, and is released upon antigen stimulation[41]. It has been
shown to have antimicrobial activity against a broad range of
microbes including Gram-positive and Gram-negative bacteria,
fungi, and parasites including M. tuberculosis and other organisms.
Priming of granulysin in CD4 is dysregulated in the CD4+ T cells
of HIV-infected patients[42].
Table 3. Potentially novel loci from GWA scan.
Cytogenet.
location SNP
Location
(hg18) Gene/region Disc. P
Disc. P
(adj.) Rep. P Combined P
Minor
allele
Freq
cases
Freq.
Controls OR (95% C.I.)
1q21 rs6701216 151045150 EDC 0.0034 0.0053 0.0069 0.00005 T 0.174 0.127 1.45 (1.21,1.75)
2p11 rs2164807 85816062 GNLY-ATOH8 0.00084 0.0015 0.0039 0.000016 G 0.467 0.394 1.35 (1.18,1.54)
2p12 rs11126740 79754603 CTNNA2 0.0018 0.0018 0.019 0.00014 T 0.311 0.37 0.77 (0.67,0.88)
3q13 rs6804331 105237077 Gene desert 0.00073 0.0013 0.0455 0.0003 C 0.445 0.381 1.30 (1.13,1.50)
13q13 rs3812888 39128294 COG6 0.001 0.0017 461024 0.00001 C 0.43 0.35 1.38 (1.15,1.66)
13q13 rs7993214 39248912 COG6 4.761025 0.0001 0.0033 261026 T 0.279 0.351 0.71 (0.62,0.82)
14q32 rs2282276 94730882 CLMN 0.0096 0.014 0.047 0.0031 G 0.099 0.073 1.40 (1.12,1.76)
15q21 rs4775912 49068271 USP8-TNFAIP8L3 0.00034 0.00065 0.0136 5.661025 G 0.194 0.146 1.41 (1.19, 1.67)
15q21 rs3803369 49163121 USP8-TNFAIP8L3 0.00012 0.00025 0.0138 2.961025 A 0.195 0.145 1.43 (1.21,1.69)
Trend P values from discovery, replication and combined analyses for U.S. PS samples (810 cases, 1256 controls) are shown. The minor allele, its frequency in cases and
controls and its odds ratios and 95% C.I.s from the combined data-set are also shown. Abbreviations are described in footnotes to Table 1.
doi:10.1371/journal.pgen.1000041.t003
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Other genes that should be evaluated in additional PS cohorts on
the basis of replication P values,0.05, and increased significance in
combined cohorts (Table 3) are calponin-like transmembrane
domain protein (CLMN)[43], the gene for the catenin member,
CTNNA2[44] and a gene desert on chromosome 3q13.
Association with Chromosome 4q27: A Recently
Identified Autoimmune Locus
In the discovery cohort there were 3 SNPs from chromosome
4q27 with P,561025 (adjusted P,1024). These were rs13151961,
rs6822844 and rs6840978 (Table S2, Figure S6). The most
significant of these was rs13151961, where adjusted P=461025
(Table 4). Association of this region with PSA was confirmed in an
independent cohort of patients from the UK (for rs13151961,
P=0.003, Table 4), where the frequency of the associated T allele
was,0.25 in cases and,0.31 in controls (OR: 0.64; 95% CI: 0.49–
0.84). Association with additional SNPs in high LD with rs13151961
(rs6840978 and rs6822844), was also replicated in this cohort.
Although association could not be replicated in our U.S. cohort with
a case/control approach, the trend in allele frequencies in cases
versus controls was similar to that seen in the U.K. cohort (for
rs13151961 the frequency of the T allele was ,0.26 in U.S. cases
and ,0.29 in our U.S. controls, Table 4).
A recent study from the Wellcome Trust Case Control
Consortium [19] identified this 4q27 region in a search for risk
factors for type 1 diabetes (T1D). In a follow-up study [45], some
support for this association with T1D was provided. In the latter
Figure 4. Association localization plots for novel replicated region on chromosome 13. Symbols are the same as those used in Figure 2.
SNPs indicated with an asterisk are rs3812888 and rs7993214.
doi:10.1371/journal.pgen.1000041.g004
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study, association of this region with Grave’s disease (GD) was also
tested, and some evidence for association with the complementary
allele of rs17388568 to that seen in T1D was obtained. The same
region was also reported to be associated with Celiac disease (CeD)
[46]. Recent evidence is also provided for a role for this region in
rheumatoid arthritis and T1D from the Netherlands[47]. In that
study the rs6822844*A allele was reported to be a perfect proxy for a
haplotype that is highly associated with autoimmune diseases[47]
with frequencies of 0.13 in cases versus 0.19 in N. European controls.
The risk alleles of rs13151961, rs13119723, rs6822844 and
rs6840978 associated with PS and PSA in the current study are
similar to those reported for CeD [46]. Overall, the risk alleles/
haplotype of GD, CeD, PS and PSA appear to be the same, and of
similar frequency. For example the frequency of the rs6822844*A
allele is 0.14 in U.S. PS patients,,0.16 in U.K. PSA patients, 0.14
in RA patients [47], ,0.13 in T1D patients from the Nether-
lands[47], 0.12 in Celiac Disease patients from the Nether-
lands[46], and ,0.14 in Irish CD patients[46]. This contrasts with
frequencies of 0.19–0.20 in European control populations[46]
[47]. Although the frequency of the rs6822844*A allele was 0.14 in
our PS cases and hence similar to frequencies seen in CeD, RA
and T1D cases, its frequency in our combined cohort of U.S.
controls was 0.16 (Table 4). This is lower than that reported for
European controls. However, it has been previously reported that
geographic variability exists at this locus across Europe [46]. Our
U.S. ‘‘European’’ controls are likely to be more disparate in origin,
and are likely to account for our inability to obtain significant
evidence for association with PS and 4q27.
To explore association of this region in our cohort of U.S. PS
cases, without the possible confounding influence of subtle
geographic variability at this locus in Europeans, we performed
family based association tests in our 242 psoriasis nuclear families
which are described elsewhere[26,48]. This approach provided
evidence for replication of association of PS with rs6822844 and
rs6840978 (PDT P=0.029 and 0.007 respectively). For these
SNPs, the over-transmitted rs6822844*G and rs6840978*C alleles
were also the risk allele from case/control studies. Haplotype
studies in families also revealed association with the rs6822844*G/
rs6840978*C haplotype (multipoint TDT P=0.006). Hence, our
findings support chromosome 4q27 as harboring a variant/
haplotype for PSA and PS.
As reported elsewhere the 4q27 locus that contains these
associated SNPs corresponds to two closely correlated ,439 kb
and ,40 kb haplotype blocks [46]. This extensive LD makes it
very difficult to determine the predisposing variant. Chromosome
4q is also the location of PSORS3, which is generally placed
slightly more distally [49]. However, the locus identified here may
contribute in part to the previous observations of linkage. The long
region of LD at chromosome 4q27 contains several genes [46]:
Testis nuclear RNA-binding protein (TENR), a gene encoding a
protein of unknown function (KIAA1109), and genes encoding the
interleukin-2 (IL2) and interleukin-21 (IL21) cytokines. TENR is
expressed primarily in testis and KIAA1109 transcripts are
ubiquitous, hence their roles in autoimmunity are not particularly
compelling. However, IL2 and IL21 are of particular interest with
respect to PS. IL2 is considered to be a pathogenic cytokine for
PS[50], and blockade of the IL2 receptor with therapeutic
antibodies has induced disease resolution in some cases[51]. IL2
is a survival factor for T cells and promotes the differentiation of
cytotoxic T-lymphocytes and NK cells. Both of these cell types are
present in psoriasis lesions. Moreover, many IL2 receptor (IL2R)
positive T-cells that fit the phenotypic definition of regulatory T
cells (Tregs) are also present in psoriasis lesions. IL-2 may influence
how a common precursor T-cell differentiates into either a Treg or
a Th17 T-cell, since addition of IL-2 has been shown to suppress
the differentiation of Th17 T-cells in mice[52]. IL-2 antibodies
stain normal epidermis and psoriatic epidermis, with generally
lower staining in the dermis (Figure 5). The pattern of staining
appears to be to dendritic cells (DCs) which are likely to be
epidermal Langerhans cells. This pattern of IL-2 staining is
probably due to DC activation and upregulation of IL2R. Cells
with IL2 receptors include T-cells, B-cells, NK-cells, and dendritic
cells.
The epidermal staining for IL-21 is much lower than for IL-2
(Figure 5) and appears to be mainly on dendritic cells in the
superficial dermis. IL-21 is a product of activated T cells (under
conditions of Th17 polarization). It then acts in an autocrine or
paracrine fashion on T-cells to up-regulate expression of the IL23
receptor which has already been implicated in psoriasis patho-
genesis. IL23R sensitizes cells to IL-23 which stimulates IL17
synthesis and/or prolongs the survival of Th17 cells [53]. Blocking
IL21 reduces the progression of lupus erythematosus [54] which is
one of the autoimmune diseases that is now being considered as a
‘‘Th17’’ mediated disease. Therefore IL21 may play a role in Th17
formation in this and other autoimmune diseases where these cells
are pathogenic.
Extensive resequencing of IL2 coding and flanking regions has
already been performed in T1D samples and no coding or obvious
regulatory/splice variants were identified [45]. As stated previ-
ously, this region needs to be resequenced thoroughly followed by
comprehensive genotyping in larger numbers of samples to
identify the autoimmune associated variant/s [45].
Figure 5. Immunostaining of normal, non-lesional and lesional
skin for IL2, IL21, COG6 and SPPL2A proteins. The size bar is 100
micrometers.
doi:10.1371/journal.pgen.1000041.g005
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Conclusions
The observed associations in the current study are of interest for
several reasons. It is noteworthy that the strongest association is
with the MHC. Even in PSA, where associations are reportedly
less than with PS (without PSA), associations with the class I region
appear to be more significant than with any other region. We were
also able to replicate previously reported associations with IL12B
and IL23R and detected a potentially novel association upstream
from IL12RB2. Novel associations within COG6 and the region
on chromosome 15q21 harboring USP8 and SPPL2A are of
interest. These and other regions reported here are worthy of
follow up in other cohorts. Moreover, the association with
chromosome 4q27 provides further evidence that this region is a
common locus for multiple forms of autoimmune disease.
A recent study reported the IL13/IL4 region from chromosome
5q31 as being associated with PS[55]. Overall, the risk contributed
by the MHC, the IL13/IL4 region and the IL23R and IL12B
variants was estimated to be 3.83. With the COG6 and
chromosome 15q21 loci described here, the risk would be
increased. However, PS is a complex disease, and overlapping
subsets of risk factors may be sufficient for susceptibility, so that
risk effects cannot be computed in an additive manner.
The ability to identify low risk variants for common diseases
such as PS and PSA will be limited by the cohort size, and larger
Figure 6. Association localization plots for novel replicated region on chromosome 15. Symbols are the same as those used in Figure 2.
SNPs indicated with an asterisk are rs4775912 and rs3803369.
doi:10.1371/journal.pgen.1000041.g006
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numbers of cases and controls will be necessary to identify the
majority of genetic factors for these diseases. Moreover, some of
the SNPs with borderline discovery P values are also likely to be
genetic risk factors for disease. It is worth noting that our discovery
P value for the associated IL23R R381Q SNP did not reach
significance (P = 0.057, adjusted P= 0.081) although allele fre-
quencies in the discovery dataset revealed a M.A.F. of 0.041 in
cases and 0.065 in controls, which is similar to what has been
reported in other studies[56]. Additional genome-wide association
scans and replication studies are required to identify additional
variants and to confirm some of those found in the current study.
Such studies include a genome-wide scan for psoriasis variants
from the Genome Wide Association Network (GAIN) consortium
[57]. Genes such as these are important for determining the
pathogenesis of PS and PSA and in identifying novel drug targets
for these inflammatory diseases of the skin and joints.
Materials and Methods
Subjects
The cohorts for the discovery and replication phases of this
study are all of European descent and are described in Table S1.
The discovery cohort consisted of 223 Caucasian individuals with
PS or PSA from the US. Cases were ascertained through Texas
Dermatology (Dallas, TX) and the dermatology clinics at the
University of California, San Francisco (UCSF). 89 of the PSA
cases had a first degree relative with psoriasis and were members
of affected sib pair families, described elsewhere[58]. All except for
two of these PSA cases also had PS. These cases were from
affected sib pair families with psoriasis and both of these cases had
several first degree relatives with PS.
Genotypes of 519 European controls obtained following
hybridization to the Illumina HumanHap300 array were from
the New York Cancer Project (NYCP) [59] and were downloaded
from http://intragen.c2b2.columbia.edu/. These were random
controls and there was no specific information about autoim-
mune/inflammatory disease. Recent large genome-wide associa-
tion studies using controls of this type have been shown to be
successful, leading to only a modest effect on power unless the
event of misclassification bias is substantial[19]. Informed consent
was obtained from all participants. Protocols were approved by the
local institution review boards of all participating institutions. All
subjects over 18 years of age gave written informed consent, filled
out a clinical questionnaire and received a skin examination by the
study dermatologist, who confirmed the diagnosis of plaque PS
and graded PS severity. All adults with PSA satisfied the inclusion
criteria of having both clinically documented inflammatory
synovitis and PS, confirmed by a rheumatologist and dermatol-
ogist respectively.
Blood samples were obtained by venipuncture for all subjects,
and genomic DNA was isolated from whole blood by standard
procedures.
Replication cohorts were from both the U.K. and the U.S. The
U.K. cohort consisted of 576 PSA patients from the UK and are
described elsewhere [60]. In brief, PSA patients under active
follow up by hospital rheumatologists were recruited from
throughout the UK although the majority came from the North-
West region of England. All patients satisfied the inclusion criteria
of having both clinically documented inflammatory synovitis and
PS. Each patient was assessed by a trained research nurse, who
undertook a standardized clinical history and examination.
Detailed demographic and clinical information was obtained and
whole blood was taken for DNA extraction and subsequent genetic
analysis. Control samples (n = 480) were obtained from blood
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donors. All patients and controls were white and of UK descent.
They were recruited with ethical committee approval (MREC 99/
8/84) and provided written informed consent.
The replication cohort from the U.S. for cases consisted of 577
patients with PS (94 of these were also diagnosed with PSA),
ascertained at the University of California, San Francisco, CA or
at Texas Dermatology, Dallas, TX The replication cohort for
controls consisted of 479 unrelated Caucasian individuals from the
University of California, San Francisco, ascertained as a set of
healthy controls, for cardiovascular studies. A separate cohort of
258 controls was ascertained in Texas. The latter controls were all
.40 years of age and were ascertained on the basis of not having
PS, PSA, or any other inflammatory or autoimmune disease.
Table S1 also provides information on how well the cases and
controls were matched in terms of age and gender. It can be seen
that the gender proportions and ages are similar in cases and
controls, for both discovery and replication studies.
Genotyping Methods
DNA was normalized to a concentration of 100 ng/ml (diluted
in 10 mM Tris/1 mM EDTA). Samples were quantitated with a
Nanodrop Spectrophotometer (ND-1000). For the discovery
phase, approximately 1 mg of genomic DNA was used to genotype
each sample on the Illumina HumanHap300v2A Genotyping
BeadChip. This was performed at the Robert S. Boas Center for
Genomics and Human Genetics at The Feinstein Institute for
Medical Research, Manhasset, NY. This assay relies on allele
specific primer extension and the use of a single fluorochrome.
Samples were processed according to the standard Illumina
Infinium II automated protocol. This involved whole genome
amplification, fragmentation, precipitation, resuspension in hy-
bridization buffer and hybridization to the Illumina Bead Chips
for a minimum of 16 h at 48uC. After hybridization the
BeadChips were processed for the single base extension reaction,
followed by staining and imaging on an Illumina Bead Array
Reader. Normalized bead intensity data were loaded into the
Illumina Beadstudio 2.0 software which converted fluorescence
intensities into SNP genotypes.
Genotyping for all the replication studies was performed with
the Sequenom MassArray system (iPlex assay). This involves
primer extension chemistry and mass spectrometric analysis
described at our web site http://hg.wustl.edu/info/Sequenom_
description.html.
Quality Control
Before analysis, we performed quality filtering of both samples
and SNPs to ensure robust association tests. Based on previous
criteria [61], we required that all samples used for the discovery
phase pass a 93% genotyping call rate threshold, and that all SNPs
pass a 95% call rate threshold.
In the case of the replication studies, 57 individuals from the
total of 2370 individuals in the replication study were removed
because of low genotyping (i.e. when over half of the genotypes for
a sample were missing). SNPs with ,75% call rates were also
excluded from analysis to obtain an average genotyping rate of
0.902. Genotypes were also evaluated for departure from HWE in
the controls and SNPs with P,0.001 were removed from further
analysis. After pruning, 244 SNPs remained.
A total of 463 ancestry informative SNPs (AIM) present on the
Illumina HumanHap300v2A Genotype BeadChip were used to
check for possible confounding population substructure in the
discovery sample with STRUCTURE software [[62]. For this
analysis, genotypes at these SNPs were analyzed for all 742
samples (223 PS cases and 519 controls).
To investigate other biases[20] that could be introduced with
shared controls we assessed the potential effect of substructure
with the genomic-control method [21] and with EIGENSTRAT
[23].
Statistical Analysis for Association
The Cochran-Armitage Test for trend[25] was conducted with
Purcell’s PLINK program (http://pngu.mgh.harvard.edu/,
purcell/plink). However, several SNPs in the current study that
exhibited significant differences in cases/controls, were also
different when allele frequencies in controls were compared with
those from European CEPH typed for SNPs in the HapMap
project. NYCP participants are quite diverse with respect to
European origin, and many SNPs are reported to show differences
among European subgroups[63]. These were identified by a
comparison of SNP allele frequencies in European CEPH
individuals typed for the HapMap project and were not selected
for follow-up studies.
Measures of linkage disequilibrium, D’ and r2, and allele
frequencies were based on precomputed scores from the
International HapMap website or were computed locally from
HapMap genotypes or from our own case and control genotypes
with Haploview 3.2 (http://www.broad.mit.edu/mpg/haploview/).
Power calculations for association were calculated at: http://
pngu.mgh.harvard.edu/,purcell/gpc/. Association localization
plots (Figures 2–4,6,S4–S5) were generated with an R code
modified from snp.plotter (http://cbdb.nimh.nih.gov/,kristin/
snp.plotter.html) and Regional Association Plot (http://www.
broad.mit.edu/diabetes/scandinavs/figures.html).
Family Based Tests
Family based association tests on 271 nuclear families were
performed with the Pedigree Transmission Disequibrium Test
[64] as described elsewhere [11,12,65].
Immunohistochemistry
Tissue sections were fixed with acetone and stained with
10 ug/mL purified mouse anti-human monoclonal antibodies to
IL-2 (R&D, clone 5334.21), IL-21 (R&D, J148-1134), COG6
(Abnova, H00057511-M01) and SPPL2A (Abgent, AP6312a).
Biotin labeled horse anti-mouse antibodies (Vector Laboratories)
were amplified with avidin-biotin complex (Vector Laboratories)
and developed with chromogen 3-amino-9-ethylcarbazole (Sigma
Aldrich).
Supporting Information
Table S1 Summary of cases and controls used in discovery and
replication stages.
Found at: doi:10.1371/journal.pgen.1000041.s001 (0.03 MB
DOC)
Table S2 Top ranking SNPs where P,561025 in discovery
cohorts (also stratified on the basis of the presence of PSA or no
PSA).
Found at: doi:10.1371/journal.pgen.1000041.s002 (0.25 MB PDF)
Figure S1 Heterozygosity of sample versus genotyping call rate.
Found at: doi:10.1371/journal.pgen.1000041.s003 (0.95 MB TIF)
Figure S2 Distribution of SNP success rate in the discovery
study.
Found at: doi:10.1371/journal.pgen.1000041.s004 (1.36 MB TIF)
Figure S3 Q-Q plot of GWA analyses in unrelated individuals
used in the discovery study obtained with PLINK. Black dots
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indicate the negative log of unadjusted trend P values
(lGC=1.101) and red dots indicate the negative logarithm of
adjusted trend P values (lGC= 1).
Found at: doi:10.1371/journal.pgen.1000041.s005 (6.03 MB TIF)
Figure S4 Association localization plot for replicated region at
chromosome 1q21. Results for SNPs used in the discovery phase
(adjusted for GC) are presented as diamonds. Negative LOG P
values are provided on the Y axis. The X axis corresponds to the
locations of SNPs. The P value for all samples (original GWA scan
plus replication samples) are shown as circles. The P value
obtained with the most highly associated SNP (from the original
GWA scan plus the replication samples) is shown as a red circle.
The SNPs shown as orange diamonds are in r2.0.8 (European
HapMap CEPH (CEU) samples) with the most significant SNP
identified in our study. The recombination rate based on the CEU
HapMap is shown in light blue along the x axis (scale on the right).
The green arrows indicate the locations of select genes. The LD
relationship of Illumina discovery SNPs derived from CEU
HapMap genotypes are shown below the graph. The most highly
associated SNP, rs6701216 is indicated with an asterisk above the
LD plot.
Found at: doi:10.1371/journal.pgen.1000041.s006 (9.70 MB TIF)
Figure S5 Association localization plots for autoimmune locus
on chromosome 4q27 showing P values obtained in discovery
sample. Symbols are the same as those used in Figure S4. The
asterisk above the LD plot corresponds to rs6840978.
Found at: doi:10.1371/journal.pgen.1000041.s007 (9.59 MB TIF)
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